Navigation Links
BioSpecifics Technologies Corp. to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Date:11/9/2011

LYNBROOK, N.Y., Nov. 9, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Eurasia, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming Lazard Capital Markets 8th Annual Healthcare Conference at 8:30am EST on Wednesday, November 16, 2011 in New York, NY.  

The live webcast of this presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com or at the link http://wsw.com/webcast/lz11/bstc/.  

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Its partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture in adults with palpable cord in the palm and is also developing XIAFLEX for the treatment of Peyronie's disease which is currently in Phase 3 pivotal clinical trials, frozen shoulder (Adhesive Capsulitis) and cellulite. Pfizer, Inc. is responsible for marketing XIAPEX® for Dupuytren's contracture in the 27 European Union member countries and 19 other European and Eurasian countries and also has commercialization and development rights for Peyronie's disease in these same territories. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan. BioSpecifics is developing XIAFLEX internally for human and canine lipomas. More information about the Company may be found on its website at www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
2. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
3. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
4. BioSpecifics Technologies Corp. Announces FDA Approval of XIAFLEX(TM) for Treatment of Dupuytrens Contracture
5. BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21st Annual Health Care Conference
6. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
7. BioSpecifics Technologies Corp. to Present at Cowen and Company 30th Annual Health Care Conference
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2009 Financial Results on March 10, 2010
9. BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytrens Contracture
10. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
11. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2010 Financial Results on May 7, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... May 9, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, today announced it has earned a spot on ... list. The Company was ranked among 500 U.S. employers ... and Healthcare Equipment and Services. The annual ... an anonymous, independent survey of over 30,000 employees across ...
(Date:5/8/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed its ... health care service center company based in ... relationship management programs for leading pharmaceutical manufacturers and health ... WRB will join Envoy Health Management, LLC , ... biotech firms, and other service companies. Together, WRB and ...
(Date:5/4/2017)...  A recent study published in the American ... as a means of disinfection anesthesia workstations ... on anesthesia workstations. In the study, UVC disinfection ... equipment surfaces contaminated with three (3) organisms commonly ... further validates the body of literature supporting Tru-D," ...
Breaking Medicine Technology:
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... for Global Policy Solutions is vehemently opposed to Donald Trump’s budget, “A New ... for despair that inspires fear, demonizes the poor, marginalizes underserved populations, undermines productivity, ...
(Date:5/24/2017)... ... ... Medic CE , a Career Step company, is sponsoring a live, 1-hour ... Journal of Emergency Medical Services (JEMS). The free webinar, to be held on Wednesday, ... Duckworth, LP, a career fire captain as well as founder and director of the ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Rob Lowe is ... “Informed,” developed for Public Television. “Informed” brings the public important topics from all aspects ... treatment of the feet and issues surrounding feet and ankles. , Podiatry is essential ...
(Date:5/24/2017)... ... 24, 2017 , ... Dymedix® Diagnostics, Inc., the ... it had completed the first phase of building a global distribution network. To ... world (ROW) authorized dealers specializing in polysomnography accessories. The company plans to ...
(Date:5/23/2017)... ... May 23, 2017 , ... PM360, the premier information resource ... the winners of its 3rd Annual ELITE Awards. The ELITE (Exceptional • Leaders ... healthcare industry today. , Out of more than 500 submissions, 100 winners were ...
Breaking Medicine News(10 mins):